94 results about "Invasion metastasis" patented technology

The invention belongs to the field of medicinal chemistry, provides novel application of a tyrosine kinase inhibitor DCC-2036, and in particular discloses application of the tyrosine kinase inhibitor DCC-2036 in preparation ofmedicines for preventing or treating triple negative breast cancer. Tests show that the tyrosine kinase inhibitor DCC-2036 is capable of inhibiting proliferation and invasion and metastasis of TNBC(Triple Negative Breast Cancer) cell systems MDA-MB-231 and HS-578T, and moreover the inhibition function of the tyrosine kinase inhibitor DCC-2036 upon cell proliferation is prior to those of most TNBCclinicalfirst-line treatment medicines. Meanwhile, tests further show thatreceptor tyrosine kinaseAXL is a key target of DCC-2036 to take effects into play in TNBC cells, the tyrosine kinase inhibitor DCC-2036 targets AXL and further regulates downstream signal paths to take the anti-tumor function into play in the TNBC and is good in targeted therapy specificity and remarkable in effect, and normal tissue is generally not damaged.

The present invention discloses a quercetin metal nano drug and a preparation method and an application thereof. In the provided quercetin metal nano drug, quercetin and transition metal elements arecoordinated by coordination bonds, and the quercetin metal nano drug is formed by surface modification of polymers containing carbonyl groups or hydroxyl groups. The nano drug is a multifunctional nanomaterial with a tumor targeting function, can inhibit growth, invasion, metastasis, recurrence, etc. of tumor cells, even eliminates the tumor cells, and has various modes of preventing the tumors such as photothermal therapy, photodynamic therapy and radiation therapy. In addition, when the nano drug is degraded and metabolized in vivo, a produced quercetin molecule can exert the anti-tumor effect for a longer period of time, aggregation, distribution and metabolism in vivo can also be traceable, an excellent diagnosis and treatment integrated nano-platform can be formed, and the quercetin metal nano drug has a good application prospect and a broad development space in the field of medicines.

The invention provides a novel high-affinity completely humanized antibody which can specifically bind with CD26 as well as a preparation method and application thereof and belongs to the technical field of genetic engineering antibodies. The CD26 is a ubiquitous multifunctional II type transmembrane glycoprotein, has various biological functions and can be interacted with various proteins such as ADA, CD45, FAP-alpha and the like. The invention provides the humanized antibody or a fragment thereof, wherein the antibody or the fragment thereof is capable of specifically binding with the human CD26, preferably the CD26 extracellular domain; the amino acid sequence of the antibody or the fragment thereof comprises an amino acid sequence containing a monoclonal antibody or a fragment thereof or a conjugate of the fragment in any one of 6 complementary determining regions in one of SED ID NO: 2, SED ID NO: 3, SED ID NO: 4, SED ID NO: 6, SED ID NO: 7, and SED ID NO: 8, or an amino acid sequence obtained through amino acid replacement or modification. The obtained anti-CD26 single-chain antibody provided by the invention can highly specifically bind with the CD26 and is simultaneously capable of obviously inhibiting the proliferation, the invasion and the metastasis of tumor cells.

The invention relates to a co-encapsulated nanometer drug carrying system, a pharmaceutical composition containing the same, a drug system containing the same and application of the co-encapsulated nanometer drug carrying system to cancer treatment and further relates to a method for preparing the nanometer drug carrying system. The invention belongs to the field of nanometer drugs and particularly relates to the field of co-encapsulated nanometer drugs. The invention specifically provides the co-encapsulated nanometer drug carrying system which comprises a nanometer carrier, a TGF-beta inhibitor and DOX, wherein the TGF-beta inhibitor and the DOX are co-encapsulated in the nanometer carrier. Further, the effect of killing tumors in a body and inhibiting tumor invasion and metastasis is realized.

The invention discloses CXCL13 oncoprotein and an application of targeted medicine for the CXCL13 oncoprotein in the tumor aspect. A method for preparing the tumor targeted medicine includes the steps of screening antibodies capable of effectively reducing the high expression of the CXCL13 oncoprotein or neutralizing the activity of the CXCL13 oncoprotein; preparing the corresponding tumor targeted medicine through the antibodies. According to the CXCL13 oncoprotein and the application, the anti-CXCL13 monoclonal antibodies can achieve the good anti-tumor effect by suppressing a p-AKT signal channel, a p-ERK signal channel and an EMT signal channel and accordingly suppressing growth, invasion and metastasis of tumor cells.

The invention relates to an application of a PNO1 inhibitor to preparation of esophagus cancer treatment medicines, belongs to the field of biopharmaceutical research, and particularly relates to an application of a PNO1 inhibitor to preparation of esophagus cancer treatment medicines. The inventor firstly finds that the PNO1 can be used as an esophagus cancer treatment target point. The PNO1 inhibitor can restrain the proliferation rate of esophagus cancer cells, can restrain the cloning and forming capacity of the esophagus cancer cells, can promote esophagus cancer apoptosis, can restrain esophagus cancer cell migration, can restrain esophagus cancer cell transfer, and can restrain esophagus cancer cell invasion and transfer, so as to treat esophagus cancer, and a new direction is opened up for treatment of esophagus cancer.

The invention relates to disubstituted phenyl biguanide compounds and application containing the same to inducing malignant tumor cell for anoikis and inhibiting tumor growth and transfer. Proved by in vitro-in vivo experiments, the disubstituted phenyl biguanide compounds show the remarkable functions of inducing the malignant tumor cell for anoikis, starting caspase cascade and inhibiting tumor growth and transfer and also have the characteristics of high efficiency and low toxicity, so the disubstituted phenyl biguanide compounds as pharmaceutical compounds are expected to be applied to a plurality of malignant tumor medicaments for inhibiting the tumor growth, invasion and metastasis and treating human melanoma, neurospongioma, lung cancer, gastric cancer, prostate cancer, ovarian cancer and the like.

The invention discloses a method for inhibiting the growth and metastasis of solid tumor cells and a special pharmaceutical composition, and belongs to the field of animal cell proliferation and transformation. When ovarian cancer HEY cells or breast cancer MDA-MB-231 cells are induced, a culture medium is replaced after acting in high-concentration CoCl2, and after the cells are recovered, the treatment is repeated twice to obtain a sufficient number of cells with high invasion and metastasis ability; and the obtained cells are cultured in a culture medium without CoCl2, then the removed culture medium is added with a pharmaceutical composition prepared from dimethyl sulfoxide, dexamethasone, rosiglitazone, 3-isobutyl-1-methylxanthine for in-vitro induction, and when obvious lipid droplets are formed in tumor cell plasma, it indicates that the tumor cells have adipose differentiation. The method is designed to induce the tumor cell adipose differentiation and the purpose of inhibitingtumor cell growth is achieved. It is confirmed by animal experiments that the method is expected to be used for clinical treatment and metastasis inhibition of human solid tumors.

The invention belongs to the field of molecular biology, and in particular relates to a long non-coding ribonucleic acid (lncRNA) breast cancer marker and knockout of lncRNA in application of treatment of breast cancer. The lncRNA is Linc00426, and the nucleotide sequence thereof is shown in SEQ ID NO. 1; the marker has a very significant up-regulation in breast cancer cells and can be used for screening the breast cancer in an auxiliary way. In addition, the knockout of the lncRNA can effectively inhibit the invasion, metastasis and proliferation of the breast cancer cells, thus being used for treating the breast cancer.

The invention discloses an experimental method for promoting growth and metastasis of colon cancer cells by lentivirus overexpression vector mediated E6-AP. The experimental method comprises the following steps: detecting the expression of E6-AP in different colon cancer cell lines, and determining low expression E6-AP of HCT-116 and HCT-8 colon cancer cells; co-transfecting human embryonic kidney293FT cells with over-expression PCDH-pCDNA3.0-FLAG-E6-AP plasmid and lentiviral packaging helper plasmids to obtain stable expression cells of lentiviral mediated overexpression of E6-AP, and detecting the overexpression of E6-AP through real-time PCR and Western blot detection; and detecting the influence of overexpression of E6-AP on the growth, migration and invasion of colon cancer cells through CCK-8, scratch healing and Transwell TM experiments. The experimental method provides a new target for colon cancer targeted therapy.

The invention specifically relates to application of melittin in preparation of a drug used for inhibiting invasion metastasis of breast cancer cells, which belongs to the field of bioengineering technology. CD147 and MMP9 proteins exert significant effects on invasion and metastasis of breast cancer MCF-7 cells. The invention aims to find a CD147 expression inhibitor which is capable of hindering or reducing secretion of MMP9 and inhibiting invasion metastasis of cancer cells to cancerous peripheral tissue. According to the invention, MCF-7 cells are cultured at first, then different doses of melittin is used, and flow cytometry, ELISA and RT-PCR experimental results prove that expression of CD147 and MMP9 is suppressed in the MCF-7 cells treated by melittin; and then Transwell invasion chamber experiments are conducted to detect the migration rate of the MCF-7 cells treated by melittin. Melittin can inhibit invasion metastasis of the MCF-7 cells. Thus, a novel anti-breast cancer drug can be developed from melittin.

A recombinant fusion protein able to resist against tumor invasion and transfer is composed of the recombinant urokinase fragment and type-2 mutant as plasminogen activator inhibitor. The fusion protein gene cDNA is amplified by PCR method, and is cloned to expression vector to obtain fusion gene expression plasmid, which is used to transform host bacteria. The methanol or temp can induce the expression of said fusion protein. After purified, a high-purity (95%) expression product is obtained.

The present invention relates to artemisinin B, which has a molecular weight of 248 g / mol. The present invention discloses applications of the artemisinin B in preparation of drugs for tumor cell invasion and metastasis inhibition. According to the present invention, the key result comprises that the artemisinin B has the lung cancer A549 cell migration and invasion inhibition effect, wherein the effect specifically comprises that the artemisinin B provides the significant inhibition effect for the cloning proliferation of A549 cells; the artemisinin B inhibits the adhesive ability of A549 cells in the concentration-dependent manner; the results of the scratch test, the Transwell migration test and the Transwell invasion test show that the artemisinin B can effectively weaken the migration and invasion ability of A549 cells in the concentration-dependent manner; the microfilament fluorescence staining experiment results show that the artemisinin B inhibits the pseudopodia formation of A549 cells in the concentration-dependent manner; and the artemisinin B can significantly affect the invasion and metastasis-related proteins, and the experiment results show that the artemisinin B directly inhibits the STAT3 phosphorylation and the beta-catenin so as to down-regulate the expressions of MMP2 and MMP9, such that the artemisinin B has the application prospects in human lung cancer cell invasion and metastasis inhibition.

The invention provides a method for screening a protease inhibitor. The method comprises the following steps of: (1) adding a substance to be tested in protease solution to be uniformly mixed and meanwhile setting the protease solution in which the substance to be tested is not added as a blank control; (2) adding substrate protein solution into the protease solution to react so as to obtain reaction solution; (3) adding reaction end solution in the reaction solution; (4) adding ninhydrin solution to react; and (5) adding double distilled water, judging a result according to an absorbance value OD570 nm, and ensuring that a sample to be tested is positive if the absorbance of the solution of the matter to be tested is less than that of the blank control. By using the method, the protease inhibitor can be conveniently and quickly screened, a substrate is not required to be manually synthesized, the cost is low, the flexibility is high, and a new approach is provided for finding a medicament for inhibiting tumor invasiveness and metastasis.

The invention discloses application of long-chain non-coding RNA XIST and miR-132 combined with the long-chain non-coding RNA XIST for inhibiting proliferation, invasion and metastasis of gastric cancer cells. The si-XIST of the long-chain non-coding RNA XIST can silence the LncRNA XIST, so that the adsorption capacity of the LncRNA XIST to miR-132 is reduced, the miR-132 can be combined with thegene of CUL4B, and finally, the expression of the CUL4B is reduced; therefore, the proliferation, invasion, metastasis and tumor formation capabilities of gastric cancer cells are inhibited, and the apoptosis of the gastric cancer cells is promoted. The application of the LncRNA XIST and miR-132 disclosed by the invention can be beneficial to targeted treatment and clinical treatment of gastric cancer.

The invention belongs to the field of gene treatment, provides a new gene therapy product, and specifically relates to a cationic liposome compound of cancer suppressor gene LKB1 eukaryotic expression plasmid as well as a preparation method and an anti-tumor effect thereof. The gene expression carrier contains genes encoding human LKB1 protein and can express the human LKB1 protein in eukaryotic cells. Based on experiments, the cationic liposome compound of cancer suppressor gene LKB1 eukaryotic expression plasmid, disclosed by the invention, has excellent functions of resisting tumor growth and invasion and metastasis so as to provide a new selection for the tumor treatment.

The invention belongs to the field of research and development of genetic engineering antibody drugs, in particular, relates to a method for treating a tumor by administering Circ-CDH1. The Circ-CDH1 is a circular RNA Circ-CDH1 nucleic acid molecule or the protein Circ-CDH1-28 KD expressed by the circular RNA Circ-CDH1 nucleic acid molecule. In particular, a monoclonal antibody Anti-Circ-CDH1 is designed against Circ-CDH1-28 KD, which can specifically detect the content of a protein encoded by endogenous circular RNA Circ-CDH1, can remarkably inhibit invasion and metastasis of cells from tumors such as glioma, breast cancer and the like, and has wide application prospects in clinical detection of tumors and invasion and metastasis treatment.

The invention discloses a tumor marker related to colorectal cancer and application. The tumor marker is lncRNA (long noncoding RNA) and is located on the seventeenth chromosome of chr17: 47785696-47797422, a nucleotide sequence of the lncRNA is shown in SEQ ID NO.1 is named as lncRNA-KAT7. According to the lncRNA-KAT7 sequence, specific real-time fluorescent quantitative PCR primer can be designed and synthesized to be used for preparing preparation for colorectal cancer diagnosis or treating effect prediction. By means of the real-time fluorescent quantitative PCR preparation, expression level of lncRNA-KAT7 is detected in colorectal cancer clinical case specimen, expression of the lncRNA-KAT7 in the colorectal cancer is found to be obviously reduced, the lncRNA-KAT7 has obvious statistic significance (p<0.05), and low expression of the lncRNA-KAT7 in the colorectal cancer is closely related to colorectal tumor differentiation, T staging, invasion and metastasis. The result shows that the lncRNA-KAT7 can serve as the tumor marker of the colorectal cancer and can be used for preparing preparation or kits applied to auxiliary diagnosis, treating effect prediction and prognosis of the colorectal cancer.

The invention discloses siRNA, siRNA plasmid and lentivirus for targeted inhibition of expression of neutral cholesteryl ester hydrolase 1 (NCEH1) gene of a human hepatocellular carcinoma cell, construction methods of the siRNA, the siRNA plasmid and the lentivirus, and application of the siRNA, the siRNA plasmid and the lentivirus to preparation of hepatocellular carcinoma treatment drugs for inhibiting proliferation, invasion and metastasis of the hepatocellular carcinoma cell. By researching the expression level of the NCEH1 in hepatocellular carcinoma tissue, such action target, the NCEH1gene, is provided for treatment of hepatocellular carcinoma; by designing the sequence of the siRNA for the targeted inhibition of the expression of the NCEH1 gene of the human hepatocellular carcinoma cell, the corresponding siRNA expression plasmid and siRNA lentivirus, the expression of the NCEH1 gene in the human hepatocellular carcinoma cell can be efficiently inhibited, and thus the proliferation, invasion and metastasis capability of the hepatocellular carcinoma cell is effectively inhibited; the siRNA, siRNA plasmid and lentivirus are of great significance in preparation of drugs for inhibiting proliferation, invasion and metastasis of the hepatocellular carcinoma cell so as to treat the hepatocellular carcinoma, and an effective method is provided for developing targeted therapy drugs for treating the hepatocellular carcinoma for NCEH1.

The invention relates to a biomarker for breast cancer metastasis and prognosis diagnosis. The biomarker is meR342-EZH2, and through a series of experiments, meR342-EZH2 can promote the EMT process ofbreast cancer and in-vitro invasion and metastasis and in-vivo far-end metastasis of breast cancer cells, through related analysis of case grading, metastasis, prognosis and the like of breast cancerpatients, the meR342-EZH2 high expression is positively correlated with tumor enlargement, high grading and more far-end metastasis sites of the breast cancer patients, and meR342-EZH2 high expression indicates a low five-year survival rate of the breast cancer patients. Therefore, meR342-EZH2 can be used for preparing or screening the breast cancer metastasis diagnostic reagents and breast cancer prognosis diagnostic reagents, and a new diagnosis and evaluation method is provided for breast cancer metastasis and prognosis.

The invention relates to application of ADAM12m used as a tumor marker and a target molecule in diagnosing and treating tumors. The ADAM12m is used as a mark of tumor invasion metastasis and participates in the processes of growth and invasion metastasis of the tumors, thus the ADAM12m can be used as a target spot in cancer diagnosis and / or treatment and for screening medicaments for resisting the tumor invasion metastasis.

The invention discloses application of a compound ilamycin C and homologues thereof in preparation of drugs for treating a triple negative breast cancer. According to an experiment that the compound ilamycin C influences MDA-MB-231 and BT-549 cells of the triple negative breast cancer, the compound ilamycin C has the capability of obviously inhibiting the proliferation, invasion and metastasis ofthe triple negative breast cancer and promoting the apoptosis by inhibiting the activation of an IL-6 / STAT3 pathway, so that the compound ilamycin C can be applied to the preparation of the drugs of an IL-6 / STAT3 pathway inhibitor of the triple negative breast cancer. The invention provides drug candidates for researching and developing new anti-triple negative breast cancer drugs, and a scientific basis for developing and utilizing natural active substances from deep sea microorganisms.

The invention discloses an application of LINC01843 as a liver cancer diagnosis and treatment marker. According to the invention, up-regulation of expression of LINC01843 in liver cancer patients is discovered for the first time, and it is prompted that the LINC01843 can be used as a biomarker for diagnosis and treatment of liver cancer. Experiments further prove that through inhibition of expression of the LINC01843, proliferation, clone formation colony number and invasion and metastasis capabilities of liver cancer cells can be remarkably inhibited, and it is prompted that intervention of LINC01843 expression may become a new way for liver cancer treatment, and meanwhile, a theoretical basis is provided for research of a liver cancer mechanism.

The invention belongs to the field of molecular biology, and particularly relates to a lncRNA lung adenocarcinoma marker and application of knockout of the lncRNA lung adenocarcinoma marker in treating lung adenocarcinoma. The lncRNA is AC009948.5, the nucleotide sequence of the lncRNA is as shown in the SEQ ID NO.1, and the marker is significantly up-regulated in lung adenocarcinoma cells and canbe used for assisting screening of the lung adenocarcinoma. In addition, it is discovered that by means of the knockout of the lncRNA, invasion, metastasis and proliferation of the lung adenocarcinoma cells can be effectively inhibited, which can be used for treating the lung adenocarcinoma.

The invention discloses application of endogenous polypeptide ECDP2 in preparation of a novel medicine for treating endometrial cancer. The amino acid sequence of the endogenous polypeptide ECDP2 is as shown in SEQ ID NO: 2. The invention also discloses a novel pharmaceutical composition for treating endometrial cancer. The polypeptide ECDP2 plays an important role in the malignant behavior mechanism of invasion and metastasis of endometrial cancer, and can become a specific marker for treating endometrial cancer, and the discovery can provide a basis for the development of new drugs for clinical diseases.

The invention belongs to the technical field of genetic engineering, and discloses a gene, expression vector and application for inhibiting proliferation, invasion and metastasis of breast cancer cells. The gene is LINC00850, which is a long-chain non-coding RNA that does not have the ability to encode proteins, and the length is greater than 200nt ;LINC00850 is located on the X chromosome, the length is 697bps, and the sequence name is NR_109813. The present invention detects the expression of LINC00850 in normal breast epithelial cells MCF-10A and breast cancer cells; compared with normal breast epithelial cells MCF-10A, the expression of LINC00850 in breast cancer cells is significantly up-regulated, and in highly invasive cells MDA-10A Expression was highest in MB‑231 and lowest in the less invasive cell MCF‑7. The invention has important significance for the diagnosis and treatment of breast cancer.

Tumor cells having tumorigenic potential but lacking invasive / metastatic potential are established by introducing an oncogene of the ras family into a BALB / c 3T3 A31-variant cell. A screening method for genes having the property of conferring invasive / metastatic potential is also provided, which comprises transfecting DNA derived from a tumor tissue obtained from the surface or inside of a mammal or derived from a tumor cell line into tumor cells having tumorigenic potential but lacking invasive / metastatic potential, isolating cells having acquired invasive / metastatic potential and extracting DNA therefrom.